NewAmsterdam Pharma Company NV
NAMS34.300USD
+2.240+6.99%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
3.88B시가총액
손실P/E TTM
자세한 내용은 NewAmsterdam Pharma Company NV 회사
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV 정보
종목 코드 NAMS
회사 이름NewAmsterdam Pharma Company NV
상장일Nov 23, 2022
CEODavidson (Michael Harvey)
직원 수68
유형Ordinary Share
회계 연도 종료Nov 23
주소Gooimeer 2-35
도시NAARDEN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Netherlands
우편 번호1411 DC
전화31352062971
웹사이트https://ir.newamsterdampharma.com/
종목 코드 NAMS
상장일Nov 23, 2022
CEODavidson (Michael Harvey)
NewAmsterdam Pharma Company NV의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
10.36K
+3400.00%
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
3.40K
+3400.00%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
+3400.00%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
10.36K
+3400.00%
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
3.40K
+3400.00%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
+3400.00%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Wed, Nov 19
마지막 업데이트: Wed, Nov 19
주주
주주 유형
주주
주주
비율
Frazier Life Sciences Management, L.P.
14.73%
RA Capital Management, LP
8.94%
Capital World Investors
8.66%
Forbion Capital Partners
8.12%
Viking Global Investors LP
5.71%
기타
53.83%
주주
주주
비율
Frazier Life Sciences Management, L.P.
14.73%
RA Capital Management, LP
8.94%
Capital World Investors
8.66%
Forbion Capital Partners
8.12%
Viking Global Investors LP
5.71%
기타
53.83%
주주 유형
주주
비율
Investment Advisor
29.12%
Investment Advisor/Hedge Fund
23.40%
Venture Capital
20.18%
Private Equity
14.73%
Hedge Fund
13.05%
Research Firm
2.37%
Family Office
1.70%
Sovereign Wealth Fund
1.00%
Individual Investor
0.56%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
314
117.45M
103.58%
-6.71M
2025Q3
283
121.74M
107.54%
+4.12M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Frazier Life Sciences Management, L.P.
16.70M
14.73%
--
--
Nov 01, 2025
RA Capital Management, LP
10.14M
8.94%
--
--
Sep 30, 2025
Capital World Investors
9.82M
8.66%
+1.43M
+17.11%
Sep 30, 2025
Forbion Capital Partners
9.21M
8.12%
-1.37M
-12.92%
Sep 30, 2025
Viking Global Investors LP
6.48M
5.71%
-503.00K
-7.21%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
5.67M
5%
-4.80M
-45.83%
Dec 02, 2025
Fidelity Management & Research Company LLC
5.39M
4.76%
+3.57M
+195.28%
Sep 30, 2025
Deerfield Management Company, L.P.
4.27M
3.76%
-849.26K
-16.60%
Sep 30, 2025
Wellington Management Company, LLP
4.02M
3.55%
+697.13K
+20.98%
Sep 30, 2025
Jennison Associates LLC
4.20M
3.7%
+1.25M
+42.51%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Global X Guru Index ETF
1.82%
ALPS Medical Breakthroughs ETF
1.81%
Virtus LifeSci Biotech Clinical Trials ETF
1.22%
First Trust Small Cap Growth AlphaDEX Fund
1.05%
First Trust NASDAQ Pharmaceuticals ETF
0.83%
Capital Group US Small and Mid Cap ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
0.55%
First Trust Small Cap Core Alphadex Fund
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
더 보기
Global X Guru Index ETF
비율1.82%
ALPS Medical Breakthroughs ETF
비율1.81%
Virtus LifeSci Biotech Clinical Trials ETF
비율1.22%
First Trust Small Cap Growth AlphaDEX Fund
비율1.05%
First Trust NASDAQ Pharmaceuticals ETF
비율0.83%
Capital Group US Small and Mid Cap ETF
비율0.68%
ProShares Ultra Nasdaq Biotechnology
비율0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.55%
First Trust Small Cap Core Alphadex Fund
비율0.43%
Invesco Nasdaq Biotechnology ETF
비율0.42%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
